Contact Us
Drug Search Results
More Filters [+]

Idarubicin

Alternative Names: idarubicin, idarubicina, idarubicine, zavedos, idamycin pfs, idamycin
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

Idarubicin is a 4-demethoxy-anthracycline analogue of daunorubicin which, when administered intravenously in combination with cytarabine, has therapeutic efficacy superior to that of standard induction and salvage treatment regimens in acute myelogenous leukaemia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1723369/)

Mechanisms of Action: mTOR Inhibitor,TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Clavis Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Idarubicin

Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czech Republic, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Norway, Poland, Portugal, Romania, Serbia, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Leukemia

Phase 2: Hepatocellular Carcinoma|Liver Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
QuANTUM-WILD

P3

Recruiting

Leukemia

2030-06-26

IDADOX

P2

Recruiting

Liver Cancer|Hepatocellular Carcinoma

2025-12-01

LIDA-BII

P2

Recruiting

Hepatocellular Carcinoma

2024-12-18

Recent News Events

Date

Type

Title

07/11/2024

News Article

 Injectable Cytotoxic Drug Market to Progress at a CAGR of 6.8%, reaching USD 38.2 Billion by 2034 - Report by Transparency Market Research, Inc.

06/17/2024

News Article

 Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

06/04/2024

News Article

 GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

05/06/2024

News Article

 GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions